The marked “entourage” effect exerted by Adelmidrol, combined with its anti-inflammatory PPAR-γ-dependent effect, may be promising in clinical and subclinical conditions, like irritable bowel syndrome (IBS) and unbalanced diets, in which lower PEA levels has been reported, either in experimental and clinical settings [36,37,38,39,40]. This evidence concerns the gene PPARG and irritable bowel syndrome.